The Sponsor Exit Decision Framework: Timing and Route

Introduction

Every sponsor exit settles two questions that are easy to blur: whether to sell now rather than hold, and which buyer should pay. They move separately. Between 2024 and 2025, Bain Capital and Cinven discussed selling Stada, the German generics and consumer health group they took private in 2017, with two sponsor buyers, set two dates for an initial public offering (IPO) and pulled both, then agreed to sell a majority to a third sponsor, CapVest, while keeping minority stakes. The route changed four times; the decision to realize most of the investment did not. The timing question is answered by the asset, the fund and the market. The route question is answered by who can pay the price that timing requires, which is why advice on a mature asset from a bank's financial sponsors group (FSG) starts with the first question even though most of the competition between banks is about the second. Holding is always one of the choices, and a pre-emptive approach or a dual-track can change the order in which both questions get answered.

Sponsors do not choose between routes in the abstract. They choose between a price available now and the expected value of keeping the company, and the routes matter only once selling beats holding. The comparison has a precise form: the value a sponsor could realize today is capital it is choosing to reinvest in the same company for another year, so waiting has to earn a return on that realizable value, not on the original cost. How private equity firms exit an investment comes up often in interviews, and a list of routes answers only half of it; the timing decision is the other half.

The Return on One More Year

Consider a fund that invested $300 million of equity five years ago in a company whose equity a buyer would now pay $750 million for: a 2.5x multiple of invested capital (MOIC) and an internal rate of return (IRR) of about 20%. The deal team believes one more year will complete the plan. The table compares selling now with three outcomes of holding for one year, assuming no interim cash flows.

The multiple rises in every case except the bad one, which is why a deal team arguing from MOIC nearly always wants to wait. The number that decides is the last column: with equal odds on the three outcomes, the expected return on the $750 million left in the company is 8%, well short of the 20% or more that buyout funds commonly target on new deals. Holding is justified only if the deal team can show that the plan-delivered case is the likely one, or that a better buyer appears only once the plan is delivered.

What Waiting Costs the Fund

The fund sees a second cost that the company arithmetic misses. Cash returned now raises distributions to paid-in capital (DPI), the cash measure limited partners (LPs) weigh when deciding whether to back the next fund; value held raises only the reported mark. If the fund has $2.0 billion paid in and has returned $1.1 billion, selling at $750 million (ignoring carry) takes DPI from 0.55x to about 0.93x, while waiting leaves it at 0.55x through the months the sponsor may be marketing its successor fund. How that clock shapes behavior is set out in the article on the two clocks of dry powder and DPI; here it enters as a cost of waiting that sits outside the company's own numbers.

That middle ground has its own process and pricing, covered in partial exits and minority stake sales, and it reappears in the Stada record below, where it ended up settling the decision.

Four sets of drivers set the timing: the asset's readiness, the fund's position, the market for buyers and financing, and the sponsor's own priorities. They rarely point the same way, and most hold decisions come down to one driver overruling another.

The Asset: Plan Delivered, Next Thesis Visible

A company is ready to sell when the value creation plan it was bought for has mostly happened and its reported earnings show it: margins reached, acquisitions integrated, the growth rate visible in results rather than projections. The plan and its value bridge are covered in the sponsor value creation playbook. Readiness also has a forward half that sellers underweight. Every buyer pays for what it can still do, so an asset sells best when the next owner's thesis is visible: a market to enter, a consolidation to lead, a margin gap to close.

Exit Readiness

The degree to which a portfolio company can be sold or listed on short notice: audited and comparable financial statements, a management team buyers will back, a delivered plan visible in reported earnings, debt documents a buyer can work with, and a credible case for what the next owner does. Readiness is built during the hold and cannot be produced in the weeks before a process.

The earnings trajectory matters as much as the level. A company whose last four quarters beat its plan sells on its forecast; one that has missed sells on its trailing numbers with a discount for doubt, which is why sponsors prefer to launch after a strong reporting period rather than just before an uncertain one.

The Fund: Age, Term and the Next Raise

A buyout fund usually runs about ten years with options to extend, and its stage colors every exit view, as the fund lifecycle from the coverage seat explains. A fund in its harvest years with a successor to raise wants realized proceeds before marketing begins. A fund late in its term with one company left faces a choice between a sale, an extension and a continuation vehicle (CV), a comparison that the private capital advisory guide works through from the LPs' side.

Carried interest pulls in two directions. A fund comfortably past its hurdle has carry to protect, which argues for locking in a good price. One below its hurdle earns carry only if the outcome improves, which can argue for waiting even when the fund's investors would rather have the cash, and that tension is one reason LPs scrutinize extensions and CVs closely. The coverage banker rarely sees a fund's waterfall, but its vintage, reported DPI and fundraising status are usually public enough to read.

The Market: Who Can Pay, and on What Financing

The price available depends on which buyers are active and how they fund themselves. A sponsor buyer's ceiling is set largely by the debt it can raise: when leveraged loan and private credit markets lend more turns at tighter spreads, every sponsor bid rises together, and when they retreat, the price in a secondary buyout (SBO) falls whatever the company's quality. Strategic buyers move with their own share prices, balance sheets and antitrust exposure, and why they can often outbid sponsors is the subject of the article on sponsor bidders inside a sell-side auction.

The IPO window is the most binary input. When it is open, a listing competes with the sale routes; when it is shut, it does not, and when it reopens, the queue of sponsor-owned companies waiting to list, tracked in the equity capital markets (ECM) guide's article on the sponsor-backed IPO backlog, competes for the same investors.

The Sponsor's Priorities: Control, Certainty and Speed

Two companies with identical numbers can still get different decisions, because sponsors weight certainty of closing, speed, control after closing and their LPs' reading of the outcome differently. Some want a clean exit: one closing, all the cash to the fund, nothing left behind.

Clean Exit

A sale in which the seller receives its full proceeds at closing and keeps no continuing economic exposure: no retained shares, no earn-out, and indemnity risk capped or transferred, often through warranty and indemnity insurance. Sponsors value it most late in a fund's life, when nothing can be left outstanding at the fund's wind-down.

Others will trade some cash today for retained upside, or accept a lower price for a signed deal with no financing or antitrust risk. Each preference points toward some routes and away from others, and naming the trade-off early stops a sponsor asking the market for incompatible things, such as top price, total certainty and a quick signing from the same process.

Priorities also change with the fund: a sponsor that wanted to keep upside in year four may want a clean break in year nine. Speed and certainty by route are compared in more detail in the blog's comparison of strategic sales, SBOs, IPOs and continuation funds.

Timing and route are separate questions but not independent ones. Each route runs on its own calendar, so choosing a route partly chooses a date, and some approaches arrive on a buyer's timetable rather than the sponsor's.

Every Route Keeps Its Own Calendar

A strategic sale or an SBO converts the stake to cash at one closing, usually several months after launch, with antitrust review stretching many strategic deals. An IPO converts only the shares sold at listing; the rest comes out through sell-downs after the lock-up, often over two to three years, so a sponsor that needs DPI soon is choosing a slow route when it lists. A CV can be timed to the fund's term, because the buyers are secondary investors assembled for the purpose; the coverage banker's role there is set out in the continuation vehicle as an exit option.

The calendar also works in reverse. A sponsor that has settled the timing (a sale within twelve months, say) has quietly ruled out any route that cannot deliver inside that window, which is why an IPO candidate whose window may not open in time is usually prepared for a sale as well.

Dual-Track as a Decision About Optionality

A dual-track prepares an IPO and a sale in parallel and chooses late. From the sponsor's side it is a purchase: the extra cost of two workstreams and the management time they absorb buy the right to take whichever price is better when the choice is made, and they put pressure on sale bidders who know the company could list instead. The workstreams, synchronization points and information barriers belong to the ECM guide's account of dual-track processes; the coverage question is whether the option is worth buying.

It is worth most when the two routes promise close outcomes and the markets for each are uncertain, and least when one route clearly dominates or the company is too small or too levered to list on its own merits. Adding a CV as a third track, as in the modern triple-track structure, extends the same logic to a third set of buyers.

Pre-Emptive Approaches and the Decision to Run a Process

Not every exit starts with the sponsor. A buyer may offer a price before any process in order to avoid an auction, a pre-emptive bid in the sense used in the article on how sponsors source deals. Accepting turns the timing question into a narrower one: is this price above what a process would probably produce, net of the time and the risk of an auction that disappoints? Sponsors often treat an approach as a floor and test it with a short, targeted process.

The opposite decision, launching a process into an uncertain market, has a cost that appears only if it fails, because bidders and lenders remember the prices they saw.

That is why many coverage conversations end in a decision not to launch yet. The Stada record shows both the cost of failed attempts and how a mature asset can still find its route.

Stada, based in Bad Vilbel near Frankfurt, sells generics, specialty medicines and consumer health brands. Bain Capital and Cinven took it private in 2017, and over roughly eight years of ownership it passed €4 billion of revenue, grew net sales at a compound 9% a year and more than doubled its EBITDA, helped by more than 25 acquisitions, according to the sellers' announcement of the CapVest sale.

Two Sponsor Buyers, Two IPO Dates

By 2024 the owners had held Stada for about seven years, and the open question was the route. Talks that year with Clayton, Dubilier & Rice and GTCR failed over differing price expectations, and the owners prepared a German listing instead. A January 2025 attempt was dropped, and in March the owners postponed again amid market volatility, while investors pressed for steep discounts to listed peers such as Sandoz, Haleon and Galderma, Börsen-Zeitung reported. The offering was planned at about €1.5 billion, mainly to reduce debt of about €5.6 billion, roughly six times EBITDA.

That structure matters for the decision. An offering of mostly new shares used to deleverage would have returned little cash to the funds at listing; they would have remained majority holders of a listed company and sold down over later years. For these owners the IPO was a route to retained upside, not to near-term distributions.

A Third Sponsor and a Retained Minority

In the summer of 2025 CapVest, a London-based sponsor, opened talks, which broke down in August over valuation and the structure of the bid; the owners then targeted a listing as early as October, according to Bloomberg's reporting as summarized by Private Equity Wire. Less than two weeks later the talks had been revived, and on September 1 Bain Capital and Cinven signed a definitive agreement to sell a majority stake to CapVest, each keeping a minority stake. Terms were not disclosed; press reports valued the deal at about €10 billion including debt, and CapVest's stake was reported at about 70%. The sale completed at the end of March 2026, CapVest announced, after Stada reported 2025 revenue of €4.3 billion and adjusted EBITDA of €961 million.

The record does not state the owners' reasons, and none should be read into it. What it shows is the sequence the framework predicts: the timing decision held steady once the asset was ready and the funds were mature, while the route moved with the market, from sponsor buyers to a listing and back, and settled where a buyer's price, financing for a deal of that size and the owners' wish to keep some upside met.

The coverage banker's contribution comes before the exit pitch. It is a standing view of each mature company that keeps timing and route apart and is updated as the inputs move, so that when the sponsor asks, the answer does not start from a blank page. The pitch itself, with valuations by route and buyer lists, belongs to the exit pitch on a mature asset; the framework is what keeps that pitch honest about holding.

A Standing Exit View for Each Mature Company

For each company past the middle of its expected hold, the view records:

Readiness gaps usually lead, because they take longest to close. Vendor due diligence is often the first step the view recommends, since it moves the slowest work ahead of the timing decision.

Vendor Due Diligence (VDD)

Due diligence commissioned by the seller before a sale, usually financial, tax and commercial reports prepared by advisers and shared with bidders, whose lenders are often allowed to rely on them. It shortens a process, surfaces problems while the seller can still fix or explain them, and lets a sponsor launch quickly when the timing turns.

The same logic applies to IPO preparation: the audit history, board composition and reporting a listing needs take longer to build than a sale's data room, so a sponsor that wants the option to list has to start before it knows it will use it.

Bringing In the Product Teams

Each route's price comes from a different part of the bank. The ECM team reads the IPO window and the valuation public investors would support; the leveraged finance desk sizes what a sponsor buyer can borrow, sometimes as staple financing; the mergers and acquisitions (M&A) team and the industry group map strategic buyers and their capacity; and the private capital advisory (PCA) team prices a CV when the sponsor wants to keep the asset. The coverage banker's job is to put those inputs on one basis, the sponsor's realized cash, its timing and the exposure retained, rather than four desks' headline valuations.

Framed that way, holding stops being the default and becomes what it is: a decision to buy the company again from the fund's own investors, at the price a buyer would pay today. A sponsor that turns down $750 million for its equity has in effect invested $750 million of its LPs' money in the same company for another year, and the useful question is whether it would make that investment if the company were offered for sale by someone else.

For a well-run asset the honest answer is usually yes for a while and then no. Exits are rarely forced by a single event; they follow the quarter in which that repurchase test turns negative, and by then the route has mostly been settled by whoever is able to pay.